BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, Iyer R. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol. 2014;5:E30-E33. [PMID: 24490050 DOI: 10.3978/j.issn.2078-6891.2013.042] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
Number Citing Articles
1 Font C, de Herreros MG, Tsoukalas N, Brito-Dellan N, Espósito F, Escalante C, Oo TH; MASCC Hemostasis Study Group. Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Support Care Cancer 2022. [PMID: 35545722 DOI: 10.1007/s00520-022-06935-5] [Reference Citation Analysis]
2 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hamad CD, Hoelscher ZC, Tchakarov A, Kala J. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma. CEN Case Rep 2022. [PMID: 34997535 DOI: 10.1007/s13730-021-00681-z] [Reference Citation Analysis]
4 Gabr JB, Bilal H, Mirchia K, Perl A. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy. J Investig Med High Impact Case Rep 2020;8:2324709620947266. [PMID: 32757799 DOI: 10.1177/2324709620947266] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Grall M, Daviet F, Chiche NJ, Provot F, Presne C, Coindre JP, Pouteil-Noble C, Karras A, Guerrot D, François A, Benhamou Y, Veyradier A, Frémeaux-Bacchi V, Coppo P, Grangé S. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrol 2021;22:267. [PMID: 34284729 DOI: 10.1186/s12882-021-02470-3] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
6 Efe O, Goyal L, Galway A, Zhu AX, Niles JL, Zonozi R. Treatment of Gemcitabine-Induced Thrombotic Microangiopathy Followed by Gemcitabine Rechallenge With Eculizumab. Kidney Int Rep 2021;6:1464-8. [PMID: 34013127 DOI: 10.1016/j.ekir.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sethi A, Moses R. Atypical Hemolytic Uremic Syndrome: Cancer-Induced or Chemotherapy-Induced? Cureus 2021;13:e13260. [PMID: 33717763 DOI: 10.7759/cureus.13260] [Reference Citation Analysis]
8 MacDougall KN, Schwartz B, Harewood J, Bukhari Z, Neculiseanu E. A Case of Gemcitabine-Induced Thrombotic Microangiopathy Treated With Ravulizumab in a Patient With Stage IV Pancreatic Cancer. Cureus 2021;13:e13031. [PMID: 33680585 DOI: 10.7759/cureus.13031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Nada A, Jetton JG. Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy. Pediatr Nephrol 2021;36:2227-55. [PMID: 33245421 DOI: 10.1007/s00467-020-04800-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Schulte-Kemna L, Reister B, Bettac L, Ludwig U, Fürst D, Mytilineos J, Bergmann C, van Erp R, Schröppel B. Eculizumab in chemotherapy-induced thrombotic microangiopathy. Clin Nephrol Case Stud 2020;8:25-32. [PMID: 32318323 DOI: 10.5414/CNCS109836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Das A, Dean A, Clay T. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. BMJ Case Rep 2019;12:e228363. [PMID: 30962211 DOI: 10.1136/bcr-2018-228363] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Hausberg M, Felten H, Pfeffer S. Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer. Case Rep Oncol. 2019;12:1-6. [PMID: 30792638 DOI: 10.1159/000495031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
13 Cidon EU, Martinez PA, Hickish T. Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature. World J Clin Cases 2018; 6(12): 531-537 [PMID: 30397609 DOI: 10.12998/wjcc.v6.i12.531] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Krishnappa V, Gupta M, Shah H, Das A, Tanphaichitr N, Novak R, Raina R. The use of eculizumab in gemcitabine induced thrombotic microangiopathy. BMC Nephrol 2018;19:9. [PMID: 29329518 DOI: 10.1186/s12882-018-0812-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
15 Facchini L, Lucchesi M, Stival A, Roperto RM, Melosi F, Materassi M, Farina S, Tintori V, de Martino M, Sardi I. Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report. J Med Case Rep 2017;11:209. [PMID: 28747219 DOI: 10.1186/s13256-017-1373-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
16 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
17 Allinovi M, Cirami CL, Caroti L, Antognoli G, Farsetti S, Amato MP, Minetti EE. Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. Clin Kidney J. 2017;10:625-631. [PMID: 28980667 DOI: 10.1093/ckj/sfw143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
18 Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience 2016;10:649. [PMID: 27433282 DOI: 10.3332/ecancer.2016.649] [Cited by in Crossref: 11] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
19 Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 2014;7:11-22. [PMID: 25859345 DOI: 10.1093/ckj/sft135] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]